Runway Incubator, Technoparkstrasse 2
Early Diagnosis of Neurodegenerative Diseases
Short Business Description:
The best chance at fighting neurodegenerative diseases it is to detect them and intervene as early as possible.
Nemosia’s PET neuroimaging solution is able to detect such disorders already at the sub-clinical stage, plus it supports researchers in developing and monitoring therapies.
Reduced diagnostic time, effective drug development and personalized treatments are just a few advantages this technology can bring to our aging society.
Neurodegeneration is a growing global pandemic affecting more women than men. In our aging population the the number of patients is growing, which increases the burden on affected individuals, caregivers, and health care systems.
Nemosia is an early-stage ETH Zurich Spin-off developing 1st in class medical imaging radiotracers for early detection of neurodegenerative diseases. The startup recommends including brain scans in our regular health check routine starting at a certain age, similar to mammographies for breast cancer screening. Nemosia’s tracers are developed for PET scanning, a highly sensitive and non-invasive medical diagnostic technique for brain, cardiac and tumor imaging that is able to identify subtle molecular changes in the brain even before structural changes appear.
Thereby Nemosia intends to provide a substantial contribution to better understanding and fighting disorders such as Alzheimer’s disease, Parkinson’s, MS and ALS. Improved imaging techniques can support pharmaceutical companies in drug development, treatment evaluation, effective patient recruitment and therapy monitoring. Furthermore, Nemosia aims to raise public awareness of neurological disorders and promote a culture in which it’s considered normal and safe to do regular brain checkups even before any visible symptoms appear.